Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017294
Filing Date
2022-11-10
Accepted
2022-11-10 07:46:01
Documents
62
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sgtx-20220930x10q.htm   iXBRL 10-Q 1939833
2 EX-31.1 sgtx-20220930xex31d1.htm EX-31.1 36602
3 EX-31.2 sgtx-20220930xex31d2.htm EX-31.2 36612
4 EX-32.1 sgtx-20220930xex32d1.htm EX-32.1 15225
  Complete submission text file 0001558370-22-017294.txt   6934580

Data Files

Seq Description Document Type Size
5 EX-101.SCH sgtx-20220930.xsd EX-101.SCH 38746
6 EX-101.CAL sgtx-20220930_cal.xml EX-101.CAL 52443
7 EX-101.DEF sgtx-20220930_def.xml EX-101.DEF 145393
8 EX-101.LAB sgtx-20220930_lab.xml EX-101.LAB 389975
9 EX-101.PRE sgtx-20220930_pre.xml EX-101.PRE 275704
56 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20220930x10q_htm.xml XML 1209744
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39746 | Film No.: 221374990
SIC: 2834 Pharmaceutical Preparations